Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 7/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19513096 | 0.82 | ESR2 (0.55) | MAPTJAK2JAK1GPR119 | |
| SCHEMBL22803333 | 0.81 | MAPT (0.69) | MAPTPDGFRBKDRSIRT5FYN | |
| SCHEMBL30302492 | 0.81 | MAPT (0.69) | MAPTPDGFRBKDRSIRT5FYN | |
| SCHEMBL31590275 | 0.81 | MAPT (0.80) | MAPTPDGFRBGRM5KDRSIRT5 | |
| SCHEMBL17620618 | 0.81 | MAPT (0.80) | MAPTPDGFRBKDRFYN | |
| SCHEMBL22803993 | 0.80 | MAPT (0.70) | MAPTPDGFRBKDRSIRT5FYN | |
| SCHEMBL30302542 | 0.80 | MAPT (0.70) | MAPTPDGFRBKDRSIRT5FYN | |
| SCHEMBL23000001 | 0.80 | MAPT (0.72) | MAPTPDGFRBKDRSIRT5FYN | |
| SCHEMBL31590860 | 0.79 | MAPT (0.71) | MAPTPDGFRBKDRSIRT5FYN | |
| SCHEMBL26813328 | 0.79 | MAPT (0.59) | MAPTPDGFRBJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2017184662-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184662-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | NR0B1, GRK4, CRKL | MAPT 4625/4885PDGFRB 2004/4885GRM5 1609/4885 |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | NR0B1, GRK4, CRKL | MAPT 4625/4885PDGFRB 2004/4885GRM5 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.